BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.
BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.
On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.
Funding Rounds (4) - $73MUpdate
Current Team (4)Update
|Apr 3, 2015||Business Wire - Naia Limited Appoints Three World-Class Business and Healthcare Thought Leaders to Its Business Advisory Board|
|Jan 10, 2012||VCCircle - Canaan Partners Raises $600M Fund; To Invest In Tech, Healthcare Cos|
|Jan 9, 2012||Xconomy - Canaan Partners Survives VC Turmoil, Raises New $600M Tech/Biotech Fund|
|Jul 23, 2010||Xconomy - Genzyme Stock Surges 15 Percent on Sanofi Buyout Speculation|
|Sep 17, 2009||Xconomy - VentiRx, Evangelist for Lean, Mean Virtual Way, Makes Progress With Cancer, Allergy Drugs|
|Jul 28, 2009||WSJ - Sanofi to Buy BiPar Sciences|
|Jul 22, 2009||Xconomy - Northwest VCs See Existential Threat, and a Change in the Entrepreneurial Mindset|
|Jun 4, 2009||Xconomy - Cell Therapeutics Shares Boom, Vulcan's Breast Cancer Bombshell, Microsoft Buys Rosetta Assets, & More Seattle-Area Life Sciences News|
1000 Marina Blvd.
Brisbane, CA 94005